NCT06424132Active, not recruiting
Thermogenic Silencer Regulatory Factors in Humans
Identification of Thermogenic Silencing Regulatory Factors as Biomarkers of Metabolic Health in Humans
Source: ClinicalTrials.gov · Last updated 14 Sept 2026
Brief summary (registry, in English)
A promising approach to correct the metabolic dysfunction associated with obesity is to activate brown fat non-shivering thermogenesis (NST). A critical limitation with NST as a therapeutic option, however, is that this beneficial process is silenced under human physiological temperature conditions and the mechanisms of how this occurs is unknown. This study will be the first to identify human NST silencing factors that may be targeted for the treatment of obesity and metabolic disorders.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 10 May 2024
- Start date
- 16 Aug 2024
- Primary completion date
- 4 Dec 2026
- Lead sponsor
- Rockefeller University
- Diseases
- Obesity
- NCT number
- NCT06424132
What you commit to
- Study type: Interventional
- Planned participants: 80
- From 16 Aug 2024 to the primary completion date, 4 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any vaccine administration within two weeks preceding the study procedure
- Currently taking any prescribed medication other than oral contraceptives. Treatments for weight loss or any other supplements that may alter weight or metabolism are not acceptable. Vitamins are acceptable.
- Has used illicit drugs within the last 6 months (marijuana users are eligible unless consumed in the last 30 days).
- Steroid use in the last 30 days to the exclusions
Other illness
- Diabetes type I (self-report)
- Diagnosis of thyroid disease (including goiter, hyperthyroidism, hypothyroidism, thyroiditis)(self-report)
- Diagnosis with cancer including skin cancer (self-report)
- Diagnosis or evidence of Raynaud's Syndrome or systemic sclerosis (self-report)
- A recent diagnosis of Coronavirus Disease 2019 (COVID-19) (last 2 weeks) or hospitalized at the time of diagnosis with COVID-19
- Any medical, psychological, or social condition that, in opinion of principle investigators, would jeopardize the health or well-being of the participant during the study procedure or the integrity of the data
- Diabetes Type II that is managed by insulin.
Other
- Currently pregnant
- Has consumed nicotine (smoking, inhaling, ingesting) within the last 6 months
Who the study is looking for
- Age between 18 years old and 35
- Lean group: BMI is between 18.5 and 24.9. HgA1c \<5.7%
- Obese group: BMI is \>30, HgA1c \<5.7%
- Obese group with Type II diabetes: BMI is \>30, HgA1c is \>6.5% If on oral medication for diabetes management, HgA1c may be \< 6.5% The following medications are also acceptable: statins, aspirin, angiotensin-converting enzyme inhibitors (ACEi), and angiotensin receptor blockers (ARB).
Age in the registry: 18 years to 35 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Rockefeller University Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.